Small-molecule GLP-1 receptor agonist · Fact sheet
Orforglipron
Also known as Foundayo · LY3502970
Orforglipron is the small-molecule GLP-1 medicine in Foundayo, FDA approved for weight management in defined adults. Trials show weight reduction, with gastrointestinal effects and important label warnings; it is not a peptide.
What is Orforglipron?
Orforglipron activates the GLP-1 receptor through a non-peptide molecule. Its evidence and approval are product-specific.
Benefits people look for
Readers often compare its oral formulation, weight effects, appetite effects, and tolerability with semaglutide and tirzepatide. Separate placebo-controlled trials cannot establish a universal ranking.
What the evidence supports
- ATTAIN-1 found greater weight reduction than placebo over 72 weeks in adults with obesity or qualifying overweight.
- Evidence supports the defined weight-management indication; broader disease-prevention claims need their own outcomes studies.
All research areas
- Adult weight management
- Obesity-related metabolic measures
- Type 2 diabetes research
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Common effects include nausea, constipation, diarrhea, vomiting, abdominal symptoms, headache, fatigue, and hair loss.
- The boxed warning addresses thyroid C-cell tumor risk; the human relevance of receptor-class rodent findings is uncertain. MTC/MEN2 history is a contraindication.
- Warnings include pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, allergy, and hypoglycemia with certain medicines.
- Drug interactions, oral-contraceptive effects, pregnancy, retinopathy history, and anesthesia require product-specific clinical assessment.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesPhase 3 weight-management trials support the approved adult indication. Results for weight and metabolic markers should be distinguished from proof of fewer heart attacks, longer life, or every diabetes-related use.
Selected research to read
Phase 3 randomized placebo-controlled trial with 72-week weight outcomes.
Phase 3 trial of orforglipron in adults with obesity or overweight and related conditions.
FDA approval & research status
FDA approved Foundayo on April 1, 2026, for reducing excess weight and maintaining weight reduction in adults with obesity or overweight with at least one weight-related condition, alongside diet and physical activity.
Approved uses covered here
- Foundayo: long-term weight reduction and maintenance in adults meeting the label’s obesity or overweight criteria
Foundayo FDA approved in 2026
FDA approved Foundayo on April 1, 2026, for reducing excess weight and maintaining weight reduction in adults with obesity or overweight with at least one weight-related condition, alongside diet and physical activity.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Longer-term outcomes in broader clinical use
- Direct comparisons for specific patient-relevant outcomes
- Uncommon harms beyond trial follow-up
The takeaway
Orforglipron adds an approved non-peptide option to the GLP-1 landscape, with clear weight evidence and substantial product-specific cautions.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: Foundayo prescribing information
Approved adult weight indication, contraindications, warnings, interactions, and clinical results.
- 2
- 3journalATTAIN-1: orforglipron for obesity treatment
Phase 3 randomized placebo-controlled trial with 72-week weight outcomes.
- 4clinical trialsATTAIN-1 registry
Phase 3 trial of orforglipron in adults with obesity or overweight and related conditions.